



PTO/SB/08a/b (07-05)

Approved for use through 07/31/2006. OMB 0651-0031

U.S. Patent and Trademark Office; U.S. DEPARTMENT OF COMMERCE

Under the Paperwork Reduction Act of 1995, no persons are required to respond to a collection of information unless it contains a valid OMB control number.

Substitute for form 1449A/8/PTO			Complete if Known		
INFORMATION DISCLOSURE STATEMENT BY APPLICANT (Use as many sheets as necessary)			Application Number	10/715229-Conf. #5733	
			Filing Date	November 17, 2003	
			First Named Inventor	Tariq M. RANA	
			Art Unit	1635	
			Examiner Name	K. Chong	
Sheet	1	of	42	Attorney Docket Number	UMY-041

U.S. PATENT DOCUMENTS					
Examiner Initials*	Cite No. ¹	Document Number Number-Kind Code ² (if known)	Publication Date MM-DD-YYYY	Name of Patentee or Applicant of Cited Document	Pages, Columns, Lines, Where Relevant Passages or Relevant Figures Appear
KC V	A1*	US-6,506,559	01-14-2003	Fire et al.	
	A2*	US-20020012968-A1	01-31-2002	Carroll et al.	
	A3*	US-20040171030-A1	09-02-2004	Baker et al.	

FOREIGN PATENT DOCUMENTS						
Examiner Initials*	Cite No. ¹	Foreign Patent Document	Publication Date	Name of Patentee or Applicant of Cited Document	Pages, Columns, Lines, Where Relevant Passages or Relevant Figures Appear	T ⁶
		Country Code ³ -Number ⁴ -Kind Code ⁵ (if known)	MM-DD-YYYY			

*EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant. * CITE NO.: Those application(s) which are marked with an single asterisk (*) next to the Cite No. are not supplied (under 37 CFR 1.98(a)(2)(iii)) because that application was filed after June 30, 2003 or is available in the IFW. ¹ Applicant's unique citation designation number (optional). ² See Kinds Codes of USPTO Patent Documents at www.uspto.gov or MPEP 901.04. ³ Enter Office that issued the document, by the two-letter code (WIPO Standard ST.3). ⁴ For Japanese patent documents, the indication of the year of the reign of the Emperor must precede the serial number of the patent document. ⁵ Kind of document by the appropriate symbols as indicated on the document under WIPO Standard ST.16 if possible. ⁶ Applicant is to place a check mark here if English language Translation is attached.

NON PATENT LITERATURE DOCUMENTS			
Examiner Initials	Cite No. ¹	Include name of the author (in CAPITAL LETTERS), title of the article (when appropriate), title of the item (book, magazine, journal, serial, symposium, catalog, etc.), date, page(s), volume-issue number(s), publisher, city and/or country where published.	T ²
KC V ↓	C1	Burgess, Kevin, et al., "Photolytic Mass Laddering for Fast Characterization of Oligomers on Single Resin Beads," <i>J. Org. Chem.</i> , Vol. 62:5662-5663 (1997)	
	C2	Caplen, Natasha J., et al., "Specific inhibition of gene expression by small double-stranded RNAs in invertebrate and vertebrate systems," <i>PNAS</i> , Vol. 98(17):9742-9747 (2001)	
	C3	Chiu, Y.L., et al., "RNAi in human cells: basic structural and functional features of small interfering RNA," <i>Mol. Cell</i> , Vol. 10:549-561 (2002)	
	C4	Duprez, Laurence, et al., "Pathology of the TSH Receptor," <i>Journal of Pediatric Endocrinology & Metabolism</i> , Vol. 12:295-302 (1999)	
	C5	Elbashir, S.M., et al., "Duplexes of 21-nucleotide RNAs mediate RNA interferences in cultured mammalian cells," <i>Nature</i> , Vol. 411:494-498 (2001)	
	C6	Elbashir, Sayda M., et al., "RNA interference is mediated by 21- and 22-nucleotide RNAs," <i>Genes & Development</i> , Vol. 15:188-200 (2001)	
	C7	Elbashir, S.M., et al., "Functional anatomy of siRNAs for mediating efficient RNAi in Drosophila melanogaster embryo lysate," <i>Embo. J.</i> , Vol. 20:6877-6888 (2001)	
	C8	Francis, Ross, et al., "aph-1 and pen-2 Are Required for Notch Pathway Signaling, γ-Secretase Cleavage of βAPP, and Presenilin Protein Accumulation," <i>Developmental Cell</i> , Vol. 3:85-97 (2002)	
	C9	Fressinaud, Edith, et al., "Molecular Genetics of Type 2 von Willebrand Disease," <i>International Journal of Hematology</i> , Vol. 75:9-18 (2002)	
	C10	Gualberto, Antonio, et al., "An oncogenic form of p53 confers a dominant, gain-of-function phenotype that disrupts spindle checkpoint control," <i>Proc. Natl. Acad. Sci. USA</i> , Vol. 95:5166-5171 (1998)	
	C11	Hannon, Gregory J., "RNA interference," <i>Nature</i> , Vol. 418:244-251 (2002)	
	C12	Hirota, Seiichi, et al., "Gain-of-function mutation at the extracellular domain of KIT in gastrointestinal stromal tumors," <i>Journal of Pathology</i> , Vol. 193:505-510 (2001)	
	C13	Hirota, Seiichi, et al., "Gain-of-Function Mutations of c-kit in Human Gastrointestinal Stromal Tumors," <i>Science</i> , Vol. 279:577-580 (1998)	
	C14	Hixon, M.L., et al., "Gain of function properties of mutant p53 proteins at the mitotic spindle cell cycle checkpoint," <i>Histology and Histopathology</i> , Vol. 15:551-556 (2000)	
	C15	Ho, L.W., et al., "The molecular biology of Huntington's disease," <i>Psychological Medicine</i> , Vol. 31:3-14 (2001)	
Examiner Signature	/Kimberly Chong/		Date Considered 08/02/2006

Under the Paperwork Reduction Act of 1995, no persons are required to respond to a collection of information unless it contains a valid OMB control number.

Substitute for form 1449A/B/PTO INFORMATION DISCLOSURE STATEMENT BY APPLICANT (Use as many sheets as necessary)				Complete if Known	
				Application Number	10/715229-Conf. #5733
				Filing Date	November 17, 2003
				First Named Inventor	Tariq M. RANA
				Art Unit	1635
				Examiner Name	K. Chong
Sheet	2	of	42	Attorney Docket Number	UMY-041

KC	C16	Holmes, Christopher P., et al., "Strategies for Combinatorial Organic Synthesis: Solution and Polymer-Supported Synthesis of 4-Thiazolidinones and 4-Metathiazanones Derived from Amino Acids," <i>J. Org. Chem.</i> , Vol. 60:7328-7333 (1995)	
	C17	Hutvagner, György, et al., "RNAi: nature abhors a double-strand," <i>Curr. Opin. Genet. Dev.</i> , Vol. 12:225-232 (2002)	
	C18	Kopp, P., "Human Genome and Diseases: Review, The TSH receptor and its role in thyroid disease," <i>Cell, Mol. Life Sci.</i> , Vol. 58:1301-1322 (2001)	
	C19	Kosaki, Kenjiro, et al., "PTPN11 (Protein-Tyrosine Phosphatase, Nonreceptor-Type 11) Mutations in Seven Japanese Patients with Noonan Syndrome," <i>The Journal of Clinical Endocrinology & Metabolism</i> , Vol. 87(8):3529-3533 (2002)	
	C20	Lania, Andrea, et al., "G protein mutations in endocrine diseases," <i>European Journal of Endocrinology</i> , Vol. 145:543-559 (2001)	
	C21	Luyten, I., et al., "Hybridization properties of base-modified oligonucleotides within the double and triple helix motif," <i>Eur. J. Med. Chem.</i> , Vol. 33:515-576 (1998)	
	C22	McManus, Michael T., et al., "Gene Silencing in Mammals by Small Interfering RNAs," <i>Nature</i> , Vol. 3:737-747 (2002)	
	C23	Müller, Jörn, et al., "Severe testotoxicosis phenotype associated with Asp ⁵⁷⁸ →Tyr mutation of the lutrophin/choriogonadotrophin receptor gene," <i>J. Med. Genet.</i> , Vol. 35:340-341 (1998)	
	C24	Nykänen, A., et al., "ATP requirements and small interfering RNA structure in the RNA interference pathway," <i>Cell</i> , Vol. 107:309-321 (2001)	
	C25	Oldridge, Michael, et al., "Dominant mutations in ROR2, encoding an orphan receptor tyrosine kinase, cause brachydactyly type B," <i>Nature Genetics</i> , Vol. 24:275-278 (2000)	
	C26	Parrish, S., et al., "Functional anatomy of a dsRNA trigger: differential requirement for the two trigger strands in RNA interference," <i>Mol. Cell</i> , Vol. 6:1077-1087 (2000)	
	C27	Puttaparthi, Krishna, et al., "Disease Progression in a Transgenic Model of Familial Amyotrophic Lateral Sclerosis Is Dependent on Both Neuronal and Non-Neuronal Zinc Binding Proteins," <i>The Journal of Neuroscience</i> , Vol. 22(20):8790-8796 (2002)	
	C28	Saenger, W., ed, "Principles of Nucleic Acid Structure," New York, Springer-Verlag (1984)	
	C29	Sahin-Tóth, Miklós, et al., "Gain-of-Function Mutations Associated with Hereditary Pancreatitis Enhance Autoactivation of Human Cationic Trypsinogen," <i>Biochemical and Biophysical Research Communications</i> , Vol. 278:286-289 (2000)	
	C30	Sharp, Phillip A., "RNA Interference - 2001," <i>Genes & Development</i> , Vol. 15:485-490 (2001)	
	C31	Sijen, T., et al., "On the role of RNA amplification in dsRNA-triggered gene silencing," <i>Cell</i> , Vol. 107:465-476 (2001)	
	C32	Simon, E.S., et al., "Creutzfeldt-Jakob Disease Profile in Patients Homozygous for the PRNP E200K Mutation," <i>Ann Neurol</i> , Vol. 47:257-260 (2000)	
	C33	Taylor, J. Paul, et al., "Toxic Proteins in Neurodegenerative Disease," <i>Science</i> , Vol. 296:1991-1995 (2002)	
	C34	Tuschl, Thomas, et al., "Targeting mRNA degradation by double-stranded RNA in vitro," <i>Genes & Development</i> , Vol. 13:3191-3197 (1999)	
	C35	Tuschl, Thomas, et al., "Small Interfering RNAs: A Revolutionary Tool for the Analysis of Gene Function and Gene Therapy," <i>molecular interventions</i> , Vol. 2(3):158-167 (2002)	
	C36	Wianny, Florence, et al., "Specific interference with gene function by double-stranded RNA in early mouse development," <i>Nature Cell Biology</i> , Vol. 2:70-75 (2000)	
	C37	Zuccato, Chiara, et al., "Loss of Huntingtin-Mediated BDNF Gene Transcription in Huntington's Disease," <i>Science</i> , Vol. 293:493-498 (2001)	

*EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

¹Applicant's unique citation designation number (optional). ²Applicant is to place a check mark here if English language Translation is attached.

Examiner Signature	/Kimberly Chong/	Date Considered	08/02/2006
--------------------	------------------	-----------------	------------